Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyCiltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

This report provides longer-term results from the CARTITUDE-1 trial of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma. This update covers 97 patients at a median follow up of ~28 months. The overall response rate was 97.9%, with an 82% stringent complete response across both standard and high-risk subgroups. These longer-term data from CARTITUDE-1 in triple-class exposed patients with RRMM demonstrate deep and durable responses to cilta-cel over time, including in high-risk subgroups.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form